Want to see EVAX full AI Analyst Report?
Evaxion Biotech (EVAX) Ratios
Evaxion Biotech Ratios
EVAX's free cash flow for Q2 2026 was $0.00. For the 2026 fiscal year, EVAX's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.85 | 2.01 | 1.18 | 4.51 | 8.03 |
| Quick Ratio | 5.85 | 2.01 | 1.18 | 4.51 | 8.03 |
| Cash Ratio | 5.46 | 1.16 | 0.79 | 3.50 | 7.44 |
| Solvency Ratio | -0.62 | -0.70 | -1.22 | -1.65 | -3.13 |
| Operating Cash Flow Ratio | -1.56 | -2.96 | -2.50 | -6.85 | -5.07 |
| Short-Term Operating Cash Flow Coverage | -34.98 | -81.38 | -111.26 | -189.51 | -174.07 |
| Net Current Asset Value | $ 13.53M | $ -5.37M | $ -9.27M | $ 3.26M | $ 26.98M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.26 | 0.81 | 0.84 | 0.47 | 0.09 |
| Debt-to-Equity Ratio | 0.44 | -6.11 | -2.30 | 1.24 | 0.11 |
| Debt-to-Capital Ratio | 0.31 | 1.20 | 1.77 | 0.55 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.24 | 1.26 | 2.26 | 0.49 | 0.03 |
| Financial Leverage Ratio | 1.67 | -7.56 | -2.73 | 2.65 | 1.24 |
| Debt Service Coverage Ratio | -5.83 | -8.03 | -19.52 | -13.26 | -23.08 |
| Interest Coverage Ratio | -10.54 | -15.31 | -24.75 | -16.75 | -28.23 |
| Debt to Market Cap | 0.18 | 1.80 | 0.37 | 0.15 | 0.01 |
| Interest Debt Per Share | 1.31 | 10.31 | 17.22 | 19.90 | 9.45 |
| Net Debt to EBITDA | 2.21 | -0.52 | -0.25 | 0.13 | 1.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | -102.80% | -310.80% | -30161.64% | 0.00% | 0.00% |
| EBITDA Margin | -94.63% | -292.64% | -29319.18% | 0.00% | 0.00% |
| Operating Profit Margin | -122.66% | -440.55% | -30406.85% | 0.00% | 0.00% |
| Pretax Profit Margin | -114.44% | -339.56% | -31390.41% | 0.00% | 0.00% |
| Net Profit Margin | -102.38% | -316.00% | -30308.22% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -102.38% | -316.00% | -30308.22% | 0.00% | 0.00% |
| Net Income Per EBT | 89.46% | 93.06% | 96.55% | 96.78% | 99.28% |
| EBT Per EBIT | 93.30% | 77.08% | 103.23% | 94.76% | 95.65% |
| Return on Assets (ROA) | -27.13% | -84.64% | -171.66% | -105.19% | -61.08% |
| Return on Equity (ROE) | -45.23% | 639.65% | 467.86% | -279.04% | -75.63% |
| Return on Capital Employed (ROCE) | -38.24% | -181.50% | -382.38% | -138.33% | -72.08% |
| Return on Invested Capital (ROIC) | -33.44% | -159.60% | -340.73% | -130.73% | -70.69% |
| Return on Tangible Assets | -27.13% | -84.64% | -171.66% | -105.19% | -61.22% |
| Earnings Yield | -25.21% | -232.84% | -94.44% | -44.17% | -22.78% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.16 | 1.80 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.27 | 0.95 | 0.02 | 0.00 | 0.00 |
| Asset Turnover | 0.27 | 0.27 | 0.01 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.60 | 1.18 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | 50.96 | 202.80 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 50.96 | 202.80 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 50.96 | 202.80 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.04 | -12.06 | -25.89 | -43.61 | -45.01 |
| Free Cash Flow Per Share | -1.04 | -12.06 | -26.01 | -44.11 | -47.80 |
| Dividend Paid and CapEx Coverage Ratio | -602.25 | 0.00 | -203.34 | -88.27 | -16.13 |
| Capital Expenditure Coverage Ratio | -602.25 | 0.00 | -203.34 | -88.27 | -16.13 |
| Operating Cash Flow Coverage Ratio | -0.89 | -1.28 | -1.63 | -2.51 | -5.94 |
| Operating Cash Flow to Sales Ratio | -0.88 | -3.87 | -242.34 | 0.00 | 0.00 |
| Free Cash Flow Yield | -21.78% | -285.13% | -75.89% | -49.70% | -21.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.94 | -0.43 | -1.06 | -2.26 | -4.39 |
| Price-to-Sales (P/S) Ratio | 4.06 | 1.36 | 320.92 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.79 | -2.75 | -4.95 | 6.32 | 3.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.59 | -0.35 | -1.32 | -2.01 | -4.62 |
| Price-to-Operating Cash Flow Ratio | -4.60 | -0.35 | -1.32 | -2.03 | -4.91 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | 0.01 | 0.06 | 0.10 | -0.12 |
| Enterprise Value Multiple | -2.08 | -0.98 | -1.34 | -2.19 | -3.27 |
| Enterprise Value | 14.84M | 9.59M | 28.71M | 49.52M | 79.22M |
| EV to EBITDA | -2.08 | -0.98 | -1.34 | -2.19 | -3.27 |
| EV to Sales | 1.97 | 2.87 | 393.34 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.23 | -0.74 | -1.62 | -1.90 | -3.40 |
| EV to Operating Cash Flow | -2.23 | -0.74 | -1.62 | -1.92 | -3.61 |
| Tangible Book Value Per Share | 2.66 | -1.54 | -6.92 | 14.05 | 66.37 |
| Shareholders’ Equity Per Share | 2.66 | -1.54 | -6.92 | 14.05 | 66.56 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.11 | 0.07 | 0.03 | 0.03 | 0.01 |
| Revenue Per Share | 1.17 | 3.12 | 0.11 | 0.00 | 0.00 |
| Net Income Per Share | -1.20 | -9.85 | -32.38 | -39.21 | -50.34 |
| Tax Burden | 0.89 | 0.93 | 0.97 | 0.97 | 0.99 |
| Interest Burden | 1.11 | 1.09 | 1.04 | 1.03 | 1.01 |
| Research & Development to Revenue | 1.33 | 3.13 | 163.23 | 0.00 | 0.00 |
| SG&A to Revenue | 0.86 | 2.19 | 138.07 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.11 | 6.56 | 0.00 | 0.00 |
| Income Quality | 0.86 | 1.22 | 0.80 | 1.11 | 0.89 |
Currency in USD